The CRISPR therapeutics sector reported divergent news this week: positive clinical data for a CRISPR‑based cholesterol treatment contrasted with a fatal adverse event in Intellia’s MAGNITUDE Phase III program. The juxtaposition — a high‑profile therapeutic milestone alongside a patient death under evaluation — highlights the modality’s rapid clinical advance and the safety scrutiny now accompanying in‑vivo editing programs. Companies and regulators are reassessing risk‑benefit profiles as trials scale.